Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Oral Hypoglycemic Agents: Sulfonylureas

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells.

PloS one·2025

Same author

Precision farming in aquaculture: assessing gill health in Atlantic salmon (<i>Salmo salar</i>) using a non-invasive, AI-driven behavioural monitoring approach in commercial farms.

Aquaculture science and management·2025

Same author

<i>Paraburkholderia phytofirmans</i> PsJN triggers local and systemic transcriptional reprogramming in <i>Arabidopsis thaliana</i> and increases resistance against <i>Botrytis cinerea</i>.

Frontiers in plant science·2025

Same author

Precision farming in aquaculture: non-invasive monitoring of Atlantic salmon (<i>Salmo salar</i>) behaviour in response to environmental conditions in commercial sea cages for health and welfare assessment.

Frontiers in robotics and AI·2025

Same author

Dysfunctional mitochondrial bioenergetics sustains drug resistance in cancer cells.

American journal of physiology. Cell physiology·2025

Same author

Benchmarking of five NGS mapping tools for the reference alignment of bacterial outer membrane vesicles-associated small RNAs.

Frontiers in microbiology·2024

Search research articles

Related Experiment Video

Updated: May 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins and new-onset diabetes.

Marcin Barylski, Dragana Nikolic, Maciej Banach

¹Department of Internal Medicine and Medical Specialties, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy. manfredi.rizzo@unipa.it.

Current Pharmaceutical Design

|September 18, 2013

Summary

Statins effectively reduce cardiovascular events but may increase the risk of new-onset diabetes mellitus (NOD). Research is ongoing to understand the mechanisms linking statin use to NOD, with benefits generally outweighing risks.

Related Experiment Videos

Last Updated: May 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiology
Endocrinology
Pharmacology

Background:

Statins are potent lipid-lowering drugs crucial for cardiovascular disease (CVD) prevention.
Statins are associated with an increased risk of new-onset diabetes mellitus (NOD).

Purpose of the Study:

To review the clinical evidence linking statin therapy to NOD.
To explore the potential molecular mechanisms underlying statin-induced NOD.
To assess the benefit-risk balance of statins in patients with and without diabetes.

Main Methods:

Literature search of PubMed and Scopus databases.
Review of clinical evidence and proposed molecular pathways.

Main Results:

Statins reduce cardiovascular event risk in both primary and secondary prevention.
Statins can adversely affect insulin sensitivity and beta-cell function, contributing to NOD.
The cardiovascular benefits of statins often outweigh the risk of NOD induction.

Conclusions:

Statin therapy is associated with an increased risk of NOD, but the benefits in reducing cardiovascular events are significant.
Further large-scale studies are required to fully elucidate the association between statin use and NOD and its underlying mechanisms.